CFO Joshua Smiley On Lilly’s Next Decade Of Growth
Strategy Includes Product-Specific Deals In $1bn Range
Lilly is planning for growth even beyond the loss of patent protection for Trulicity in 2027. In addition to internal R&D, Smiley said a third of new drugs will come from business development.
